Carmila S.A. (0QAP.IL)
| Previous close | 16.53 |
| Open | 16.62 |
| Bid | 16.34 x 0 |
| Ask | 16.92 x 0 |
| Day's range | 16.56 - 16.82 |
| 52-week range | 12.64 - 17.00 |
| Volume | |
| Avg. volume | 25,942 |
| Market cap | 2.523B |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | 24.28 |
| EPS (TTM) | 0.68 |
| Earnings date | 24 Jul 2024 |
| Forward dividend & yield | 1.17 (8.79%) |
| Ex-dividend date | 15 May 2023 |
| 1y target est | N/A |
PR NewswireCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended March 31, 2024, and highlighted recent business updates.
Business WireCarmila: Withdrawal of funds for the liquidity contract
PARIS, May 08, 2024--Regulatory News: On November 3rd, 2023, Carmila SA (Paris:CARM) (ISIN: FR0010828137) has entered into a Liquidity Contract with Kepler Cheuvreux (the "Contract"). This Contract, with an initial amount of 971 454,65 Euros and 124 528 number of Shares, aims to promote the liquidity of the Shares of Carmila SA on the regulated market of Euronext Paris.
- PR Newswire
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treatment of liver fibrosis. The data was presented in a poster session at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting on May 8, 2024, in Baltimore, MD.
